BTIG Maintains Buy on Cartesian Therapeutics, Raises Price Target to $44
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Julian Harrison maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $42 to $44.
BTIG analyst Julian Harrison maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $42 to $44.